Conference Proceedings
Preliminary Analysis of the Australasian Leukaemia and Lymphoma Group (ALLG) MM17 Trial: Response Adaptive Salvage Treatment with Carfilzomib-Thalidomide-Dexamethasone (KTd) for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients Failing Front-Line Bortezomib-Based Induction Therapy
Andrew Spencer, Hang Quach, Noemi Horvath, Ian H Kerridge, Flora Yuen, Edwin Sze-Hung Lee, Edward S Morris, Anna Kalff, Krystal Bergin, Shreerang Sirdesai, Malgorzata Gorniak, Sridurga Mithraprabhu, Tiffany Khong, John Reynolds
BLOOD | AMER SOC HEMATOLOGY | Published : 2018
Abstract
Abstract
Background
Data from the Australian and New Zealand (ANZ) Myeloma and Related Diseases Registry (MRDR) shows that 85% of newly diagnosed multiple myeloma (NDMM) patients (pts) in ANZ are induced with bortezomib(V)-containing therapies, predominantly triplets of V-cyclophosphamide-dexamethasone (VCD). Of these, 15% demonstrate treatment failure - either a sub-optimal response (